Probatebeta
Target

INSR

Insulin receptor

As of the edition of 20 October 2026, INSR (insulin receptor, UniProt P06213) has 32 drugs tested at it and 12 companies on the list, 5 on route A and 1 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P06213
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
94
Disease areas
Nutrition and metabolism; Hormones; Immune system; Nervous system; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Cancer
Registered trials of its drugs
1,420

Drugs at this target

StatusCount
Marketed18
Active2
Went quiet6
Stopped4
Status not established2
Total32
DrugStatusFurthest phaseUS protection
Insulin humanMarketedPhase 4Ended 1994
Insulin glargineMarketedPhase 4Ended 2012
Insulin aspartMarketedPhase 4Ended 2012
Insulin degludecMarketedPhase 4Ends 2027
Insulin detemirMarketedPhase 4Ended 2017
Insulin lisproMarketedPhase 4Ended 2008
Insulin glulisineMarketedPhase 4Ended 2016
Insulin icodecMarketedPhase 4Ends 2038
LY900014ActivePhase 3none listed
Insulin peglisproStoppedPhase 3none listed
LinsitinibActivePhase 3none listed
Insulin porkMarketedPhase 4none listed

12 of 32 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Route B1
Engaged5
Undetermined1
Total on the list12
Three companies on route A or B, with the route only
CompanyRoute
Bristol Myers SquibbRoute A
BioconRoute A
AstellasRoute A

The other 9 companies at INSR

In the product

12 companies in all; 9 are not named here, and no score is.

See the 12 companies at INSR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at INSR

Other targets in nutrition and metabolism

Companies holding approvals at INSR